The opening session of #ESMO24 has officially kicked off the conference with ESMO - Eur. Oncology president Andrés Cervantes!

Congratulations Ann Partridge MD, MPH !! So well deserved!! Dana-Farber’s Breast Oncology Center #ESMO24

For HER2+ MBC, Barbara Pistilli reviews the current 1️⃣2️⃣3️⃣ first, second, and third line ESMO - Eur. Oncology guidelines, which are closely aligned with National Comprehensive Cancer Network (NCCN) #ESMO24

📋 Patients with polycythemia vera who received ruxolitinib achieved durable hematocrit control and had improved symptom control compared to those receiving the best available therapy, according a #SOHO2024 abstract by Claire Harrison. ➡️ Read more: buff.ly/4gkU1RN #MPNsm

❓☢️🧠 Dr. Rebecca Dent asks Nancy Lin, MD about risk of radiation necrosis in Destiny Breast 12— Dr. Lin acknowledges risk and notes there was only 1 case report in the study, but also that in her practice she tries to space ADCs and XRT by 3-4 weeks due to this risk. #ESMO24

In her discussion of ICARUS BREAST01, Dr Cristina Saura commended the extensive academic effort to study biomarkers and highlighted the importance of translational research for better patient selection #bcsm #ESMO24 #ESMOAmbassadors ESMO - Eur. Oncology

Outstanding Matteo Lambertini, MD PhD discussing a crucial aspect in survivorship: fertility preservation and consequences of cancer treatments on fertility and future pregnancies 👏🏻🤰🏻 📌A topic we should always take into account when counseling a young pt💁🏼‍♀️ #ESMO24 Università di Genova

“Fertility preservation and beyond in female patients with cancer” Matteo Lambertini, MD PhD #ESMO24

Dr Jian Zhou presents the phase 3 APOLLO study in advanced #HCC at #ESMO24 ESMO - Eur. Oncology Angela Lamarca #ESMOAmbassadors

Anlotinib plus penpulimab vs sorafenib as 1L for HCC #ESMO24 🔎Phs III ALTN-AK105-III-02 👉mPFS 6.9 vs 2.8 mo 👉mOS 16.5 vs 13.2 mo 🧐In line w/ prior anti-VEGF/ICI trials, not better... 🧐Who many VEGF/ICI combos do we need in 1st line? ESMO - Eur. Oncology #ESMOAmbassadors @ILCA EASL Education

Cowabunga! Riding Breast Cancer's Biggest Data’s Wave 🏄🏻‍♂️🌊🤙🏻from #ESMO24 CAPIitello-290 drops a bombshell: TXL + capivasertib combo flops in metastatic TNBC.🎯❌ AKT pathway dead-end or OS endpoint gamble? OncoAlert VJ Oncology OncLive.com @myESO @Oncoinfo

PD-L1 vedotin in NSCLC and HNSCC. Going 1L in combination with pembro in the HNSCC dose expansion - same population as $MRUS $PFE #ESMO24

So thrilled to be at #ESMO24—my first ESMO! Stopped by the ASCO booth just in time to meet this NEW ASCO member from Sri Lanka. Welcome! I hope to see many of you while here!

Optimal sequencing of therapeutic strategies in biomarker unselected MSS CRC Great oral presentation by Chiara Cremolini #ESMO24 ESMO - Eur. Oncology

We kicked off #ESMO24 with a presentation by Robin Guo, who shared the first phase 1 clinical results of a first-in-class intravenous SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation. Read the abstract: buff.ly/4epatyr Memorial Sloan Kettering Cancer Center

Congrats Piotr Rutkowski and team for presenting their #investigatorinitiated AXAGIST #study on #axitinib and #avelumab in refractory #GISTs. Disease control rate of up to 70% in this hard to treat group! #sarcoma #ESMO24 #drugdevelopment #CTOSTweeTOS

#ESMO24: Dr Marianne Pavel presented more data from NETTER2. Nothing new, but good to know results are reliable & consistent. Now, we wait for OS & late toxicity results & COMPOSE trial to give more info about sequencing. NET Cancer Day NANETS NET Research Foundation NET CONNECT

🏃‍♀️ Can a tailored exercise program help improve quality of life for survivors of breast cancer? 📋 Research by a team from UCLA and University of Hawaii Cancer Center addressed the question. ➡️ Learn more: buff.ly/3ziEfFT